Publication date: Aug 18, 2026
Observational studies are central to assessing vaccine effectiveness and informing public health policy. The two most common designs are test-negative case-control and cohort studies, yet direct comparisons of their performance using the same population, data sources, and analytic strategies remain rare. This study compares these two designs within a national population using harmonized analytic approaches. Nationwide, matched test-negative case-control and retrospective cohort studies were conducted in Qatar between 1 January 2021 and 18 December 2021 to assess the effectiveness of the coronavirus disease (COVID-19) primary series of BNT162b2 and mRNA-1273 against any severe acute respiratory syndrome coronavirus 2 infection, symptomatic infection, and severe COVID-19. In the test-negative design, BNT162b2 effectiveness was 71. 0% [95% confidence interval (CI): 70. 1-71. 9] against any infection, 75. 6% (95% CI: 74. 2-77. 0) against symptomatic infection, and 96. 3% (95% CI: 95. 2-97. 2) against severe COVID-19. In the cohort design, after adjustment for testing rate, corresponding effectiveness was 78. 0% (95% CI: 77. 1-78. 9), 81. 2% (95% CI: 79. 8-82. 5), and 98. 0% (95% CI: 96. 6-98. 8), respectively. Both designs demonstrated similar, rapid, and largely linear waning of effectiveness in both magnitude and pattern. Test-negative design estimates lay between cohort estimates with and without adjustment for testing rate. Similar results were observed for mRNA-1273. Both designs yielded consistent effectiveness estimates across vaccines and clinically relevant outcomes, with only modest differences related to handling of health-seeking behavior. These findings demonstrate that, when rigorously implemented using quality data and harmonized analytic strategies, both designs produce comparable effectiveness estimates.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| pathway | KEGG | Coronavirus disease |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | MESH | Arts |
| disease | MESH | severe acute respiratory syndrome |
| disease | MESH | coronavirus infection |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Hexocyclium |
| disease | MESH | syndrome |
| drug | DRUGBANK | Ilex paraguariensis leaf |
| drug | DRUGBANK | Trestolone |
| disease | MESH | char |